Neuropeptide Y as a Marker in Pediatric Neuroblastoma

Abstract

Neuropeptide Y (NPY) was investigated as a possible tumor marker in pediatric patients with tumors of the sympathetic nervous system. Seven patients with neuroblastoma, 3 patients with ganglioneuroblastoma, and 2 with ganglioneuroma, were compared with 12 matched healthy controls and 34 tumor controls. NPY-like immunoreactivity (NPYLI) was analyzed in extracted plasma using a competitive radioimmunoassay. At diagnosis, plasma NPYLI was significantly increased (p <. 001) in the neuroblastoma patients (352 ± 99 pM; mean ± SEM) when compared with healthy controls (36 ± 4 pM) and tumor controls (30 ± 2 pM). Ganglioneuroblastoma and ganglioneuroma patients had lower levels (57 ± 8 pM) than neuroblastoma patients but still significantly higher than the controls. In all patients with sympathetic tumors, the NPYLI level was decreased after treatment. Five neuroblastoma patients relapsed; all had increasing NPYLI levels. In 3 of these patients, increasing NPYLI was the first sign of relapse. Plasma NPYLI correlated well to urinary levels of homovanillic acid. NPY in plasma (NPYLI) may be a clinically useful marker of pediatric neuroblastoma for diagnosis and differential diagnosis. NPYLI correlates well with the clinical course and can be the first sign of relapse. Plasma determinations of NPYLI make it possible to monitor rapid alterations of disease.

Key Words:

• ganglioneuroblastoma
• neuroblastoma
• neuropeptide Y
• neuropeptide Y-like immunoreactivity
• radioimmunoassay
• tumor marker